STI571 400 mg + STI571 600 mg
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Philadelphia Positive Chronic Myeloid Leukemia
Conditions
Philadelphia Positive Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Trial Timeline
Aug 9, 1999 → Sep 23, 2013
NCT ID
NCT00171249About STI571 400 mg + STI571 600 mg
STI571 400 mg + STI571 600 mg is a phase 2 stage product being developed by Novartis for Philadelphia Positive Chronic Myeloid Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00171249. Target conditions include Philadelphia Positive Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00171249 | Phase 2 | Completed |
Competing Products
20 competing products in Philadelphia Positive Chronic Myeloid Leukemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Imatinib Mesylate | Novartis | Phase 2 | 52 |
| Nilotinib | Novartis | Phase 3 | 77 |
| Nilotinib | Novartis | Phase 3 | 77 |
| Induction Phase + Re-Induction Phase + Post-Remission + Maintenance | Novartis | Phase 2 | 52 |
| nilotinib | Novartis | Phase 2 | 52 |
| Asciminib + Nilotinib | Novartis | Phase 3 | 77 |
| imatinib mesylate | Novartis | Phase 2 | 52 |
| Blinatumomab + Asciminib | Novartis | Phase 1/2 | 41 |
| Asciminib | Novartis | Phase 1 | 33 |
| Asciminib Pediatric formulation group + Asciminib Adult formulation group | Novartis | Phase 1/2 | 41 |
| Nilotinib + LDE225 | Novartis | Phase 1 | 33 |
| Nilotinib | Novartis | Approved | 85 |
| Imatinib + Nilotinib + Bosutinib + Dasatinib + Asciminib | Novartis | Phase 3 | 77 |
| Asciminib | Novartis | Approved | 85 |
| Blinatumomab | Amgen | Phase 2 | 51 |
| Treatment with blinatumomab given subcutaneously. | Amgen | Phase 2 | 51 |
| Blinatumomab + Blinatumomab + HyperCVAD | Amgen | Phase 3 | 76 |
| Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimen | Amgen | Phase 3 | 76 |
| Bosutinib | Pfizer | Phase 1/2 | 40 |
| Bosutinib + Bosutinib | Pfizer | Phase 1 | 32 |